EAM Investors’s Aimmune Therapeutics AIMT Stock Holding History

EAM Investors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-165,625	Closed	-$3.39M	–	402
2016 Q4	$3.39M	Buy	+165,625	New	+$3.39M	0.45%	55

Other funds holding AIMT

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM Investors's AIMT Position: Q1 2017 in Review

EAM Investors sold out of Aimmune Therapeutics (AIMT) in Q1 2017, closing a stake of 165,625 shares — an estimated $3.39M sold.

EAM Investors first reported a position in AIMT in Q4 2016 and held it in 1 quarter. The position peaked at $3.39M in Q4 2016. 90 funds tracked by Wall St. Rank hold AIMT as of Q1 2017.

EAM Investors reported no remaining Aimmune Therapeutics position as of Q1 2017 after selling out during the quarter.
EAM Investors sold 165,625 Aimmune Therapeutics shares in Q1 2017, an estimated $3.39M.
EAM Investors first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 1 quarter.
EAM Investors's Aimmune Therapeutics position peaked at $3.39M in Q4 2016.
90 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2017.

Based on EAM Investors's 13F filing for Q1 2017, filed 10 May 2017.